Richard Douglas
Richard Douglas's purchase track record
How the stock did after each of Richard Douglas's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/19/2026 | ALDX | $98K | +7.1% | -24.6% | +15.6% |
| 8/13/2025 | MXCT | $111K | +14.5% | -47.1% | +7.3% |
| 3/29/2023 | MXCT | $345K | +2.9% | -30.2% | +6.1% |
| 11/22/2021 | MXCT | $222K | -41.4% | -56.5% | -15.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
MaxCyte Appoints New Chief Corporate Development Officer. MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Biotech Sector News Dominates; No Specific ALDX Updates. Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.
Transaction History
| NVAX | ▲ Buy | Option Exercise | 18,880 | — | 6/20/2026 | View on chart |
| MXCT | ▲ Buy | Grant | 30,421 | $0 | 6/17/2026 | View on chart |
| ALDX | ▲ Buy | Open Market | 70,000 | $98K | 3/19/2026 | View on chart |
| MXCT | ▲ Buy | Open Market | 80,000 | $111K | 8/13/2025 | View on chart |
| MXCT | ▲ Buy | Grant | 29,210 | $0 | 6/18/2025 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 10,420 | $0 | 6/12/2025 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 6,670 | $0 | 6/12/2024 | View on chart |
| MXCT | ▲ Buy | Grant | 21,367 | $0 | 6/11/2024 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 3,100 | — | 6/10/2023 | View on chart |
| MXCT | ▲ Buy | Open Market | 80,000 | $345K | 3/29/2023 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 700 | — | 6/17/2022 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 1,500 | $38K | 12/13/2021 | View on chart |
| MXCT | ▲ Buy | Open Market | 20,000 | $222K | 11/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports
Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports. Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.